Breaking Down Synovial Sarcoma’s Defenses: A study on Immune Evasion and Targeted Treatment

A landmark study from Jerby-Arnon, Neftel, Shore, and colleagues at the Broad Institute of Harvard and MIT, Massachusetts General Hospital, Dana-Farber Cancer Institute, and the University of Lausanne used single-cell RNA sequencing to profile 16,872 individual cells from 12 human synovial sarcoma tumors – one of the most detailed cellular portraits of this disease ever produced. The findings reshape how we understand why synovial sarcoma evades the immune system, and point toward a specific drug combination that may be able to reverse it.

What the Study Found

The research team profiled every major cell type within synovial sarcoma tumors – cancer cells, T cells, macrophages, and more – to map how the tumor and immune system interact. Three findings stand out.

The immune system is trying. T cells inside synovial sarcoma tumors show clear signs of antitumor activity – appearing even more primed for attack than T cells found in melanoma, where immunotherapy has been transformative. The problem is not a weak immune response. The problem is that immune cells are being physically blocked from entering the tumor in sufficient numbers.

The SS18–SSX fusion gene is directly responsible for this exclusion. The fusion drives what the researchers call a “core oncogenic program” – a coordinated set of molecular activities that suppresses immune recognition, blocks cancer cell maturation, and fuels proliferation. This program is present in every tumor examined, is associated with dedifferentiation, and predicts worse clinical outcomes including higher risk of metastatic disease.

The relationship between tumor and immune cells is bidirectional. Even the small numbers of T cells and macrophages that do infiltrate can push back – their secretion of TNF and interferon-gamma actively suppresses the core oncogenic program. The tumor and the immune system are locked in a tug-of-war. Currently the tumor is winning, but the immune system is not powerless.

A Drug Combination That May Change the Balance

Using computational network modeling, the team identified HDAC1 and CDK6 as key regulators of the core oncogenic program, then tested the combination of an HDAC inhibitor (panobinostat) and a CDK4/6 inhibitor (abemaciclib) on synovial sarcoma cells. Even at low doses, the combination synergistically suppressed the core oncogenic program, triggered immunogenic cell states, enhanced antigen presentation, and was selectively toxic to synovial sarcoma cells compared to normal cells. Adding TNF amplified these effects further. The researchers propose this combination could prime synovial sarcoma tumors to become more visible and vulnerable to immune attack – and that pairing it with immunotherapy is a rational next step worth investigating clinically.

Why This Matters for the SS Community

This study reframes the immune biology of synovial sarcoma in three important ways.

The finding that T cells are active – and more capable than those in some other tumor types – challenges the assumption that immunotherapy cannot work in this disease. The barrier is T cell exclusion, not T cell dysfunction. Those are very different problems with very different solutions, and this distinction should shape how clinical trials in synovial sarcoma are designed going forward.

The core oncogenic program gives researchers and clinicians a concrete molecular target. This is no longer a generic observation that sarcoma is immunologically cold. There is now a specific mechanism, a specific regulator, and a specific drug combination that can interfere with it.

Finally, the finding that MAGE-A4 is induced as part of the core oncogenic program – directly linking aggressive tumor biology to a clinically actionable cancer-testis antigen – is significant. It suggests that the cells most responsible for tumor aggressiveness may also be the most targetable by antigen-directed therapies, a connection with direct implications for the therapies being developed for synovial sarcoma today.

For more information, please refer to the original publication. For more information about the Synovial Sarcoma Foundation, please visit our website.